AM404 attenuates reinstatement of nicotine seeking induced by nicotine-associated cues and nicotine priming but does not affect nicotine- and food-taking

Journal of Psychopharmacology

Volumn 27, Issue 6, 2013, Pages 564-571

  Gamaleddin, Islam ^a,b   Guranda, Mihail ^a   Scherma, Maria ^c,d   Fratta, Walter ^d   Makriyannis, Alexandros ^e   Vadivel, Subramanian K ^e   Goldberg, Steven R ^c   Le Foll, Bernard ^a,f  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b AIN SHAMS UNIVERSITY   (Egypt)

^c Etiology Branch   (United States)

^d UNIVERSITY OF CAGLIARI   (Italy)

^e NORTHEASTERN UNIVERSITY   (United States)

^f UNIVERSITY OF TORONTO   (Canada)

Author keywords

AM404; endocannabinoids; Nicotine; nicotine seeking; nicotine taking

Indexed keywords

N (4 HYDROXYPHENYL)ARACHIDONAMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG SEEKING BEHAVIOR; DRUG SELF ADMINISTRATION; FOOD INTAKE; MALE; NONHUMAN; PLACE PREFERENCE; PRIORITY JOURNAL; RAT; REINFORCEMENT; TOBACCO DEPENDENCE;

AM404; ENDOCANNABINOIDS; NICOTINE; NICOTINE SEEKING; NICOTINE TAKING;

ANIMALS; ARACHIDONIC ACIDS; CONDITIONING (PSYCHOLOGY); CUES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG-SEEKING BEHAVIOR; FEEDING BEHAVIOR; INJECTIONS, INTRAPERITONEAL; MALE; NICOTINE; RATS; RATS, LONG-EVANS; RECURRENCE; REINFORCEMENT SCHEDULE; SELF ADMINISTRATION;

EID: 84878085175     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881113477710     Document Type: Article

References (40)

1. Astarita G, Di Giacomo B, Gaetani S, et al. Pharmacological characterization of hydrolysis-resistant analogs of oleoylethanolamide with potent anorexiant properties. J Pharmacol Exp Ther. 2006a ; 318: 563-570
2. Beltramo M, de Fonseca FR, Navarro M, et al. Reversal of dopamine D(2) receptor responses by an anandamide transport inhibitor. J Neurosci. 2000 ; 20: 3401-3407
3. Beltramo M, Stella N, Calignano A, et al. Functional role of high-affinity anandamide transport, as revealed by selective inhibition. Science. 1997 ; 277: 1094-1097
4. Bisogno T, MacCarrone M, De Petrocellis L, et al. The uptake by cells of 2-arachidonoylglycerol, an endogenous agonist of cannabinoid receptors. Eur J Biochem. 2001 ; 268: 1982-1989
5. Bortolato M, Campolongo P, Mangieri RA, et al. Anxiolytic-like properties of the anandamide transport inhibitor AM404. Neuropsychopharmacology. 2006 ; 31: 2652-2659
6. Cippitelli A, Bilbao A, Gorriti MA, et al. The anandamide transport inhibitor AM404 reduces ethanol self-administration. Eur J Neurosci. 2007 ; 26: 476-486
7. Cohen C, Perrault G, Voltz C, et al. SR141716, a central cannabinoid (CB(1)) receptor antagonist, blocks the motivational and dopamine-releasing effects of nicotine in rats. Behav Pharmacol. 2002 ; 13: 451-463
8. Corrigall WA, Coen KM. Nicotine maintains robust self-administration in rats on a limited-access schedule. Psychopharmacology (Berl). 1989 ; 99: 473-478
9. De Petrocellis L, Bisogno T, Davis JB, et al. Overlap between the ligand recognition properties of the anandamide transporter and the VR1 vanilloid receptor: Inhibitors of anandamide uptake with negligible capsaicin-like activity. FEBS Lett. 2000 ; 483: 52-56
10. Deutsch DG, Glaser ST, Howell JM, et al. The cellular uptake of anandamide is coupled to its breakdown by fatty-acid amide hydrolase. J Biol Chem. 2001 ; 276: 6967-6973
11. Di Marzo V, De Petrocellis L, Bisogno T, et al. Metabolism of anandamide and 2-arachidonoylglycerol: An historical overview and some recent developments. Lipids. 1999 ; 34: S319 - S325
12. Di Marzo V, De Petrocellis L, Bisogno T, et al. A structure/activity relationship study on arvanil, an endocannabinoid and vanilloid hybrid. J Pharmacol Exp Ther. 2002 ; 300: 984-991
13. Di S, Boudaba C, Popescu IR, et al. Activity-dependent release and actions of endocannabinoids in the rat hypothalamic supraoptic nucleus. J Physiol. 2005 ; 569: 751-760
14. Fegley D, Gaetani S, Duranti A, et al. Characterization of the fatty acid amide hydrolase inhibitor cyclohexyl carbamic acid 3'-carbamoyl-biphenyl-3-yl ester (URB597): Effects on anandamide and oleoylethanolamide deactivation. J Pharmacol Exp Ther. 2005 ; 313: 352-358
15. Forget B, Coen KM, Le Foll B. Inhibition of fatty acid amide hydrolase reduces reinstatement of nicotine seeking but not break point for nicotine self-administration - comparison with CB(1) receptor blockade. Psychopharmacology (Berl). 2009 ; 205: 613-624
16. Forget B, Hamon M, Thiebot MH. Cannabinoid CB1 receptors are involved in motivational effects of nicotine in rats. Psychopharmacology (Berl). 2005 ; 181: 722-734
17. Forget B, Wertheim C, Mascia P, et al. Noradrenergic alpha1 receptors as a novel target for the treatment of nicotine addiction. Neuropsychopharmacology. 2010 ; 35: 1751-1760
18. Freund TF, Katona I, Piomelli D. Role of endogenous cannabinoids in synaptic signaling. Physiol Rev. 2003 ; 83: 1017-1066
19. Fu J, Gaetani S, Oveisi F. Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-alpha. Nature. 2003 ; 425: 90-93
20. Gamaleddin I, Guranda M, Goldberg SR, et al. The selective anandamide transport inhibitor VDM11 attenuates reinstatement of nicotine seeking behaviour, but does not affect nicotine intake. Br J Pharmacol. 2011 ; 164: 1652-1660
21. Giuffrida A, Piomelli D. The endocannabinoid system: A physiological perspective on its role in psychomotor control. Chem Phys Lipids. 2000 ; 108: 151-158
22. Hajos N, Kathuria S, Dinh T, et al. Endocannabinoid transport tightly controls 2-arachidonoyl glycerol actions in the hippocampus: Effects of low temperature and the transport inhibitor AM404. Eur J Neurosci. 2004 ; 19: 2991-2996
23. Kathuria S, Gaetani S, Fegley D, et al. Modulation of anxiety through blockade of anandamide hydrolysis. Nat Med. 2003 ; 9: 76-81
24. Khaled MA, Farid Araki K, Li B, et al. The selective dopamine D3 receptor antagonist SB 277011-A, but not the partial agonist BP 897, blocks cue-induced reinstatement of nicotine-seeking. Int J Neuropsychopharmacol. 2010 ; 13: 181-190
25. Le Foll B, Goldberg SR. Rimonabant, a CB1 antagonist, blocks nicotine-conditioned place preferences. Neuroreport. 2004 ; 15: 2139-2143
26. Le Foll B, Goldberg SR. Cannabinoid CB1 receptor antagonists as promising new medications for drug dependence. J Pharmacol Exp Ther. 2005 ; 312: 875-883
27. Le Foll B, Forget B, Aubin HJ, et al. Blocking cannabinoid CB1 receptors for the treatment of nicotine dependence: Insights from pre-clinical and clinical studies. Addict Biol. 2008 ; 13: 239-252
28. Lopez-Rodriguez ML, Viso A, Ortega-Gutierrez S, et al. Design, synthesis, and biological evaluation of new inhibitors of the endocannabinoid uptake: Comparison with effects on fatty acid amidohydrolase. J Med Chem. 2003 ; 46: 1512-1522
29. Mascia P, Pistis M, Justinova Z, et al. Blockade of nicotine reward and reinstatement by activation of alpha-type peroxisome proliferator-activated receptors. Biol Psychiatry. 2011 ; 69: 633-641
30. Melis M, Pillolla G, Luchicchi A, et al. Endogenous fatty acid ethanolamides suppress nicotine-induced activation of mesolimbic dopamine neurons through nuclear receptors. The Journal of Neuroscience: the official journal of the Society for Neuroscience. 2008 ; 28: 13985-13994
31. Moore SA, Nomikos GG, Dickason-Chesterfield AK, et al. Identification of a high-affinity binding site involved in the transport of endocannabinoids. Proc Natl Acad Sci U S A. 2005 ; 102: 17852-17857
32. Moreira FA, Grieb M, Lutz B. Central side-effects of therapies based on CB1 cannabinoid receptor agonists and antagonists: Focus on anxiety and depression. Best Pract Res Clin Endocrinol Metab. 2009 ; 23: 133-144
33. Nathan PJ, O'Neill BV, Napolitano A, et al. Neuropsychiatric adverse effects of centrally acting antiobesity drugs. CNS Neurosci Ther. 2011 ; 17: 490-505
34. Ortar G, Ligresti A, De Petrocellis L, et al. Novel selective and metabolically stable inhibitors of anandamide cellular uptake. Biochem Pharmacol. 2003 ; 65: 1473-1481
35. Roberts DC, Bennett SA. Heroin self-administration in rats under a progressive ratio schedule of reinforcement. Psychopharmacology (Berl). 1993 ; 111: 215-218
36. Scherma M, Justinova Z, Zanettini C, et al. The anandamide transport inhibitor AM404 reduces the rewarding effects of nicotine and nicotine-induced dopamine elevations in the nucleus accumbens shell in rats. Br J Pharmacol. 2012 ; 165: 2539-2548
37. Scherma M, Panlilio LV, Fadda P, et al. Inhibition of anandamide hydrolysis by cyclohexyl carbamic acid 3'-carbamoyl-3-yl ester (URB597) reverses abuse-related behavioural and neurochemical effects of nicotine in rats. J Pharmacol Exp Ther. 2008 ; 327: 482-490
38. Solinas M, Panlilio LV, Tanda G, et al. Cannabinoid agonists but not inhibitors of endogenous cannabinoid transport or metabolism enhance the reinforcing efficacy of heroin in rats. Neuropsychopharmacology. 2005 ; 30: 2046-2057
39. Vlachou S, Stamatopoulou F, Nomikos GG, et al. Enhancement of endocannabinoid neurotransmission through CB1 cannabinoid receptors counteracts the reinforcing and psychostimulant effects of cocaine. Int J Neuropsychopharmacol. 2008 ; 11: 905-923
40. Zygmunt PM, Chuang H, Movahed P, et al. The anandamide transport inhibitor AM404 activates vanilloid receptors. Eur J Pharmacol. 2000 ; 396: 39-42